Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:HELP

Cybin 8/8/2024 Earnings Report

Cybin logo
$4.67 -0.39 (-7.71%)
Closing price 04:00 PM Eastern
Extended Trading
$4.70 +0.03 (+0.54%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Date
8/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3285629/0/en/correction-helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-health.html
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284731/0/en/helus-pharma-to-participate-at-the-29th-annual-milken-institute-global-conference.html
Nobody Understands Why Trump Is Invading Iran (here’s the answer)
Most investors are reacting to the Iran strikes without understanding the underlying motive driving the decision. Addison Wiggin, Founder of Grey Swan Investment Fraternity, says there is a hidden reason behind the bombing - and knowing it could change how you position your money right now.tc pixel
May 15 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health
April 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/28/3282483/0/en/helus-pharma-partners-with-tara-mind-to-advance-veteran-mental-health.html
Does Robert Langer’s Arrival Reframe Confidence in Cybin’s (HELP) Clinical Strategy and Execution Risk?
April 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/does-robert-langer-arrival-reframe-120533038.html
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
April 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/23/3279786/0/en/helus-pharma-strengthens-scientific-advisory-board-with-addition-of-dr-robert-langer-and-dr-stephen-brannan.html
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. Cybin’s work spans preclinical research through clinical trials, with an emphasis on optimizing pharmacology, dosing and delivery to improve safety, tolerability and the patient experience. Its R&D approach combines chemistry, formulation science and clinical development to advance candidate therapies toward regulatory review.

Cybin’s therapeutic efforts target a range of mental health indications that commonly include mood and anxiety disorders and substance-use disorders. The company pursues both internal development programs and collaborative relationships with academic and industry partners to support clinical development, regulatory strategy and potential commercialization pathways.

As a publicly traded biotechnology company, Cybin’s operations encompass research and development activities across multiple jurisdictions, with clinical programs conducted in regions where regulatory frameworks permit investigational studies of psychedelic-assisted treatments. The company positions itself to expand therapeutic options for patients and to contribute to the evolving scientific and clinical understanding of psychedelic-derived medicines.

View Cybin Profile
Earnings Tools